PhRMA uneasy about "right-to-try" laws

Share this article:

The Pharmaceutical Research and Manufacturers of America is uneasy about state laws which permit patient access to medications which the FDA has not approved. Colorado enacted a “right to try” law in May that allows patients and pharmaceutical companies to coordinate care, and NBC reports that other states are contemplating similar legislation.

PhRMA tells BioCentury that it has “serious concerns” about such measures because clinical trials are essential for determining a drug's safety. The lobbying group also said such laws are “unlikely to add any meaningful new approaches that can optimize the federal expanded access programs,” referring to the FDA's expanded access program, which is also known as “compassionate use.” 

The FDA program has the same goal—to give patients with serious or immediately life-threatening diseases access to untested, unapproved medication. The FDA plays middleman in this scenario, and approves or rejects requests on an individual basis.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.